Last update 08 Aug 2026

PF-08046876

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms-
Action
inhibitors
Mechanism
ITGB6 inhibitors(integrin subunit beta 6 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Adenocarcinoma of EsophagusPhase 1
United States
20 Aug 2025
Adenocarcinoma of EsophagusPhase 1
Canada
20 Aug 2025
Adenocarcinoma of EsophagusPhase 1
Spain
20 Aug 2025
Adenocarcinoma of EsophagusPhase 1
United Kingdom
20 Aug 2025
Advanced Lung Non-Small Cell CarcinomaPhase 1
United States
20 Aug 2025
Advanced Lung Non-Small Cell CarcinomaPhase 1
Canada
20 Aug 2025
Advanced Lung Non-Small Cell CarcinomaPhase 1
Spain
20 Aug 2025
Advanced Lung Non-Small Cell CarcinomaPhase 1
United Kingdom
20 Aug 2025
Advanced Malignant Solid NeoplasmPhase 1
United States
20 Aug 2025
Advanced Malignant Solid NeoplasmPhase 1
Canada
20 Aug 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free